Download Epigenetic Marks and Cancer Drugs

Keystone Symposia is pleased to present
Epigenetic Marks and Cancer Drugs

Scientific Organizer: Ali Shilatifard
March 20–25, 2013 | Eldorado Hotel & Spa | Santa Fe, New Mexico, USA
T
he regulation of transcription by RNA polymerase
II is the key controlling step in development, and its
misregulation results in the pathogenesis of a number
of human diseases including cancer. Several factors including
the transcriptional initiation and elongation machineries,
chromatin remodeling complexes and chromatin modifiers
have been shown to be central in the regulation of gene
expression. Much has been learned about the molecular role
of chromatin remodelers and modifiers in transcriptional
control and human health. Most such studies find their
origination in the first discovery of histone deacetylase
(HDAC) and its inhibitor trichostatin A (TSA). To date,
other small molecular inhibitors of chromatin modifiers
and interactors have been identified, and some are being
used successfully in clinic. The overall goal of this meeting is
to gather experts in the area of genetics and biochemistry of
chromatin and transcriptional regulators and further discuss
how this process is involved in development and how
small molecule inhibitors of transcription and chromatin
modifiers can be used for the treatment of human diseases
including cancer.
Session Topics:
> Chromosomes, Chromatin and Transcription
> Polycomb and Trithorax in Gene Expression and Cancer
> Histone Marks in Development and Cancer
> DNA Methylation in Development and Cancer
> Enhancers and ncRNAs in Development and Cancer
> Myc, Transcriptional Regulation and Development
> Transcription, Chromatin and Epigenetics in Cancer Therapy
Keynote Speaker: Stuart L. Schreiber
presenting on “Linking Genetic Features of Human Cancers and
Histone-Modifying Enzymes for Future Cancer Therapies”
Abstract & Scholarship Deadline: November 19, 2012
Late-Breaking Abstract Deadline: December 21, 2012
Early Registration Deadline: January 22, 2013
1.970.262.1230 | 1.800.253.0685 (US & Canada)
Keystone Symposia on Molecular and Cellular Biology is a nonprofit organization
headquartered in Colorado, USA directed and supported by the scientific community.
Note: Scholarships are available to students and postdoctoral fellows and require a brief
application and submission of an abstract. Short talk speakers will also be selected from
abstracts. Early registration saves US$150 on later fee. Information shown is current as
of October 12, 2012 but subject to possible change. Please visit meeting website for the
most up-to-date program information.
www.keystonesymposia.org/13C8
Keystone Symposia on Molecular and Cellular Biology is a nonprofit organization headquartered in Colorado, USA directed and supported by the scientific community.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Epigenetic Marks and Cancer Drugs (C8)
March 20-25, 2013 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA
Scientific Organizers: Ali Shilatifard
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
Abstract & Scholarship Deadline: November 19, 2012 / Late-Breaking Abstract Deadline: December 21, 2012 / Early Registration Deadline: January 22, 2013
WEDNESDAY, MARCH 20
Arrival and Registration
THURSDAY, MARCH 21
Welcome and Keynote Address
Stuart L. Schreiber, HHMI/Harvard University, USA
Linking Genetic Features of Human Cancers and Histone-Modifying
Enzymes for Future Cancer Therapies
Shiv I. S. Grewal, NCI, National Institutes of Health, USA
Epigenetic Genome Control by RNAi and Heterochromatin Proteins
Anne Schaefer, Mount Sinai School of Medicine, USA
Short Talk: PRC2 is Essential for Adult Brain Function
Johnathan R. Whetstine, Massachusetts General Hospital, USA
Short Talk: Looking at Cancer through the Eyes of Histone
Demethylases
Charles Lin, Baylor College of Medicine, USA
Short Talk: Transcription Amplification in Tumor Cells with Elevated
c-Myc
Chromosomes, Chromatin and Transcription I
*Shelley L. Berger, University of Pennsylvania, USA
Poster Session 1
B. Franklin Pugh, Pennsylvania State University, USA
Hemisomes and Nucleosomal Assymeetry across the Saccharomyces FRIDAY, MARCH 22
cerevisiae Genome
Polycomb and Trithorax in Gene Expression and Cancer
Patrick Cramer, Max Planck Institute for Biophysical Chemistry,
*Shiv I. S. Grewal, NCI, National Institutes of Health, USA
Germany
Ali Shilatifard, Northwestern University, USA
New Insights into the Mechanisms of Transcription and its Regulation
Chromatin Modifications, Transcriptional Elongation Control and
Anne Brunet, Stanford University, USA
Childhood Leukemia
Epigenetic Regulation of Aging
Danny F. Reinberg, HHMI/New York University, USA
Siavash K. Kurdistani, University of California, Los Angeles, USA
PRC1 in Drosophila and Mammals
Short Talk: Regulation of Intracellular pH by Histone Acetylation
Jürg Müller, Max Planck Institute of Biochemistry, Germany
Alejandro Vaquero, Bellvitge Institute for Biomedical Research, Spain Molecular Mechanisms of the Polycomb System
Short Talk: SirT2 Regulates Cell Cycle Progression and Genome
Peter Verrijzer, Erasmus University Medical Center, Netherlands
Stability by Modulating Mitotic Deposition of H4K20 Methylation
Antagonism between Polycomb and Trithorax in Development and
Disease
Workshop 1
*Mary Ann Osley, University of New Mexico School of Medicine, USA Kami Ahmad, Harvard Medical School, USA
Short Talk: The Chromatin Configuration of Polycomb Response
Masami Horikoshi, University of Tokyo, Japan
Elements (PREs) Define Epigenetic States
“Modification Web” and “Signal Router” Theories on Histone
François Fuks, Université Libre De Bruxelles, Belgium
Modification System and their Application to Development of Cancer
Short Talk: Molecular Basis of Tets: In Search of their Protein Partners
Drugs
Zhiguo Zhang, Mayo Clinic, USA
Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical
Short Talk: Histone Modifications Regulate DNA Replication Coupled
School, USA
Nucleosome Assembly
Reversible Disruption of mSWI/SNF-Like BAF Complexes by the
SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Histone Marks in Development and Cancer
Gary Hon, University of California, San Diego, USA
*Ramin Shiekhattar, University of Miami, USA
Whole Genome Bisulfite Sequencing Reveals Tissue-Specific DNA
Thomas Jenuwein, Max Planck Institute of Immunobiology and
Methylation in a Normal Mouse
Epigenetics, Germany
Tal H. Salz, Johns Hopkins University, USA
Making and Breaking Heterochromatin
hSET1 Regulates the Canonical Wnt-Signaling Pathway and Plays a
Tony Kouzarides, University of Cambridge, UK
Role in Colorectal Cancer
Chromatin Modification Pathways and their Role in Cancer
Eleni Maniati, Queen Mary University of London, UK
Alexander Tarakhovsky, Rockefeller University, USA
Functional Effect of Aberrant Mll2/3 Gene Expression in Pancreatic
Signaling Control of Epigenetic Fitness
Cancer
Shelley L. Berger, University of Pennsylvania, USA
Cheng-Fu Kao, Academia Sinica, Taiwan
Chromatin Landscape in Cellular Aging
H2B Monoubiquitylation Regulates the Replication Stress Response
Mary Ann Osley, University of New Mexico School of Medicine, USA
Chromosomes, Chromatin and Transcription II
Short Talk: The Histone Modification Landscape of Quiescent Yeast
*Ali Shilatifard, Northwestern University, USA
Cells Formed during Chronological Aging
Richard A. Young, Whitehead Institute for Biomedical Research, USA
Connecting Transcription, Chromatin and Cancer
* Session Chair † Invited but not yet accepted Program current as of May 4, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/13C8.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Epigenetic Marks and Cancer Drugs (C8)
March 20-25, 2013 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA
Scientific Organizers: Ali Shilatifard
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
Abstract & Scholarship Deadline: November 19, 2012 / Late-Breaking Abstract Deadline: December 21, 2012 / Early Registration Deadline: January 22, 2013
Poster Session 2
SATURDAY, MARCH 23
DNA Methylation in Development and Cancer
*B. Franklin Pugh, Pennsylvania State University, USA
Yi Zhang, HHMI/Harvard Medical School, Children's Hospital Boston,
USA
Role of Tet1-Mediated 5mC Oxidation in PGC Reprogramming and
Meiosis
Peter A. Jones, Van Andel Research Institute, USA
DNA Methylation and Cancer Therapy
Jean-Pierre Issa, Temple University School of Medicine, USA
Epigenetic Reprogramming as Cancer Therapy
Roger A. Greenberg, University of Pennsylvania Perelman School of
Medicine, USA
Short Talk: Acetylation Determines Double-Strand Break Repair
Choice and Response to PARP Inhibition
Gregory David, New York University School of Medicine, USA
Short Talk: Epigenetic Regulation of Inflammation Modulates
KRas-Driven Pancreatic Cancer Progression
Diana Hargreaves, Stanford University, USA
Short Talk: BAF Complexes Cooperate with Topoisomerase II alpha
to Decatenate DNA
Li-Jung Juan, Academia Sinica, Taiwan
Short Talk: Mechanisms of DNA Demethylation Enzymes TET Family
Proteins in Suppressing Tumor Malignancy
Enhancers and ncRNAs in Development and Cancer
*Peter Verrijzer, Erasmus University Medical Center, Netherlands
Ramin Shiekhattar, University of Miami, USA
Brave New World of Noncoding RNA
Jeannie T. Lee, Massachusetts General Hospital, USA
Xist RNA in the Establishment and Maintenance of X Chromosome
Inactivation
Robert A. Martienssen, Cold Spring Harbor Laboratory, USA
Inheritance and Reprogramming of Heterochromatin with Small RNA
Celso A. Espinoza, Ludwig Institute for Cancer Research, USA
Short Talk: Architectural Studies of Intramolecular Interactions
between Enhancers and Promoters via ChIP-HiC
Bruno Amati, Italian Institute of Technology and European Institute of
Oncology, Italy
Epigenome and Transcriptome Regulation in Myc-Driven Tumors
James E. Bradner, Novartis Institutes for BioMedical Research, USA
Targeting Gene Regulatory Pathways
Lin-Feng Chen, University of Illinois at Urbana-Champaign, USA
Short Talk: Brd4 Maintains Constitutively Active NF-kappaB in Cancer
Cells by Binding to Acetylated RelA
Junwei Shi, Cold Spring Harbor Laboratory, USA
Short Talk: Collaboration between the BAF Complex and Brd4
Maintains Myc Expression in Leukemia
Katherine A. Jones, The Salk Institute, USA
Short Talk: Beta-Catenin Ubiquitylation and Release from LEF-1/TCF
by a Novel alpha-Catenin:APC Complex
Workshop 2
*Roger A. Greenberg, University of Pennsylvania Perelman School of
Medicine, USA
Klaas Kok, University Medical Center Groningen, Netherlands
The Impact of SETD2-Inactivating Mutations and Loss of H3K36
Trimethylation on Gene Expression in Clear Cell Renal Cell
Carcinoma Progenitor Cells
Hao A. Duong, Harvard Medical School, USA
Temporal Coordination of Histone De-Acetylase and
Methyl-Transferase in Circadian Transcriptional Repression
Seung Hyuk Choi, The Salk Institute, USA
Role for alpha-Catenin in APC-Mediated Repression at Wnt Target
Genes
Emily A. Clough, NIDDK, National Institutes of Health, USA
The H4K16 Histone Acetyltransferase Chameau Is a Putative Target
of Doublesex
Anil K. Panigrahi, Baylor College of Medicine, USA
Dissecting the Role of H3K79 Methylation in Transcription Elongation
and Leukemia
Transcription, Chromatin and Epigenetics in Cancer Therapy
*Robert N. Eisenman, Fred Hutchinson Cancer Research Center,
USA
Laurie A. Boyer, Massachusetts Institute of Technology, USA
Developmental Transitions in Heart Development
Robert J. Gould, Fulcrum Therapeutics, USA
Poster Session 3
Drugging the Human Methylome: Discovery and Characterization of
Inhibitors of Protein Methyltransferases for the Treatment of
SUNDAY, MARCH 24
Genetically Defined Cancers
Patrick Trojer, Constellation Pharmaceuticals, USA
Myc, Transcriptional Regulation and Development
Targeting Histone Lysine Methylation in Cancer
*Kapil N. Bhalla, Houston Methodist Hospital Research Institute, USA
Marie Classon, Genentech, Inc., USA
Robert N. Eisenman, Fred Hutchinson Cancer Research Center, USA Short Talk: Chromatin Modifications and the Establishment of
Cooperative Transcriptional Regulation of Metabolism Mediated by
Drug-Tolerance
the Myc-Max/MondoA-Mlx Network
Kapil N. Bhalla, Houston Methodist Hospital Research Institute, USA
Michael D. Cole, Dartmouth Medical School, USA
Short Talk: Highly Effective Combination of LSD1 Antagonist SP-2509
An Epigenetic Model for Myc Autoregulation and Gene Repression
and Pan-HDAC Inhibitor Against Human AML Cells
* Session Chair † Invited but not yet accepted Program current as of May 4, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/13C8.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Epigenetic Marks and Cancer Drugs (C8)
March 20-25, 2013 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA
Scientific Organizers: Ali Shilatifard
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
Abstract & Scholarship Deadline: November 19, 2012 / Late-Breaking Abstract Deadline: December 21, 2012 / Early Registration Deadline: January 22, 2013
MONDAY, MARCH 25
Departure
* Session Chair † Invited but not yet accepted Program current as of May 4, 2017. Program subject to change. Meal formats are based on meeting venue.
For the most up-to-date details, visit www.keystonesymposia.org/13C8.